Temporomandibular Joint Disorders, Otoneurological Diseases, Quality of Life, Bruxism
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: Temporomandibular joint disorder diagnosis; otoneurologic symptoms for at least three months; at least 15 years of age; both genders; no current treatment for temporomandibular disorder or otoneurologic disease.
Exclusion criteria
Exclusion criteria: Allergy to lidocaine or botulinum toxin; anyone who changed therapies during the study to avoid false-positive; imunossupressed patients; diabetes mellitus; cognitive impairment; pregnancy or breast feeding; psychiatric disorders; skin conditions; clotting disturbances; neuromuscular diseases; using clacium channel blokers; antibiotics (aminoglycosides); cyclosporin; chloroquines; hydroxichloroquine; D-penicillamine; or anu=y other substance that interferes with neuromuscular transmission; Myasthenia gravis; Eaton Lambert syndrome; Amyotrophic sclerosis; or any disturbances that promote periferal neuromuscular dysfunction; oral anticoagulante; derivates from acetylsalicylic acid; derivates from vitemin E ou Ginko Biloba
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary outcome was a reduction of at least 30% in the intensity of tinnitus determined through a questionnaire, at any intensity when compared to the initial condition, to verify whether the outcome actually happened. | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary outcomes are not expected | — |
Countries
Brazil
Contacts
Hospital Universitário Professor Edgard Santos/UFBA